Hemorrhagic Cystitis After Stem Cell Transplantation: When Blood in the Urine Signals a Hidden Crisis
Introduction
Hematopoietic stem cell transplantation (HSCT) — bone marrow transplantation — is one of medicine’s most powerful and most demanding treatments: a complete replacement of the blood and immune system that can cure leukemia, lymphoma, aplastic anemia, and inherited metabolic disorders that would otherwise be fatal. Yet this life-saving procedure carries a constellation of serious complications, and among the most feared — because of its potential to escalate from nuisance to life-threatening emergency — is hemorrhagic cystitis.
Hemorrhagic cystitis (HC) is a well-known complication of HSCT. Its overall incidence has been reported to vary from 7–68%. This extraordinary range — from 7% to 68% — reflects the diversity of conditioning regimens, transplant types, viral exposures, and institutional practices across the published literature. What is consistent across all series is the clinical challenge HC presents: HC symptoms comprise hematuria, dysuria, burning during urination, urinary frequency, urgency and incontinency, abdominal or suprapubic pain, urinary obstruction, and renal or bladder damage.
Understanding HC — its two distinct causes, its grading system, its risk factors, and its expanding therapeutic arsenal — is essential not only for hematologists and transplant physicians but for the urologists who are increasingly called upon to manage its most severe manifestations.
Two Diseases, One Name: Early vs. Late Hemorrhagic Cystitis
The Critical Distinction
The term “hemorrhagic cystitis after HSCT” encompasses two fundamentally different conditions with different etiologies, timing, prevention strategies, and management approaches:
Early Hemorrhagic Cystitis (Chemical):
- Occurs within the first 48–72 hours after conditioning chemotherapy
- Caused by the direct toxic effects of cyclophosphamide metabolites — particularly acrolein, which is excreted in the urine and damages the urothelium
- Busulfan, when combined with cyclophosphamide, further increases HC risk
- Generally self-limiting if appropriately prevented
- Prevention is highly effective: mesna (2-mercaptoethane sulfonate sodium) inactivates acrolein in the urine; hyperhydration dilutes toxic metabolites; continuous bladder irrigation mechanically clears acrolein before it can damage the mucosa
Late Hemorrhagic Cystitis (Viral):
- Occurs days to months after transplantation — typically 2–8 weeks post-HSCT
- Caused primarily by BK polyomavirus reactivation, with adenovirus as a secondary cause
- Hemorrhagic cystitis is a common cause of morbidity after allogeneic stem cell transplantation, frequently associated with BK virus infection.
- Far more difficult to prevent and treat than early HC
- Severity often correlates with degree of immunosuppression — the immune system’s inability to control viral reactivation drives progressive urothelial damage
This two-disease framework is clinically essential: a patient developing HC on day +35 after allogeneic HSCT is almost certainly experiencing BK virus reactivation — not late acrolein toxicity — and requires a completely different management approach.
The Biology of BK Virus-Associated HC
From Dormancy to Destruction
BK polyomavirus is a ubiquitous pathogen: BK virus (BKV)-related haemorrhagic cystitis (HC) is an important cause of morbidity following allogeneic haematopoietic stem cell transplantation (HSCT).
Most humans are infected with BK virus in childhood — typically via the respiratory route — and the virus establishes latent infection in the urothelium and kidney tubular epithelium. In immunocompetent individuals, this latency is controlled entirely asymptomatically by T-cell immunity.
HSCT destroys the patient’s immune system through conditioning chemotherapy and then reconstitutes it slowly over months from the donor graft. During this prolonged immunodeficient period, BK virus reactivates in the urothelium — replicating actively and progressively destroying the bladder mucosa. As the immune system begins to reconstitute, the immune response to BK-infected urothelial cells paradoxically worsens hemorrhage — inflammatory effector cells attacking BK-infected mucosa cause additional bleeding even as they control viral replication.
Adenovirus: The Rarer But More Aggressive Cause
Adenovirus — particularly serotypes 11 and 34/35 — can also cause severe HC after HSCT, typically in the context of disseminated adenoviral infection. In addition, allogeneic patients with adenoviruria were at increased risk for the development of HC. Adenovirus-associated HC tends to be more severe than BK virus HC and is associated with higher mortality — partly because adenoviral disease often involves multiple organs simultaneously.
Grading: How Severe Is the Hemorrhagic Cystitis?
The Four-Grade System
HC is graded on a four-point clinical severity scale:
| Grade | Clinical Features | Management Implication |
| Grade I | Microscopic hematuria only | Monitoring; hydration |
| Grade II | Macroscopic (visible) hematuria | Active management; urological consultation |
| Grade III | Macroscopic hematuria with clots | Urgent urological intervention; bladder irrigation |
| Grade IV | Clot retention with urinary obstruction; renal failure risk | Emergency management; possible surgical intervention |
Of patients who developed HC, 60 had severe HC, including major urinary obstruction (4/60), renal failure (13/60), or need for surgical or chemical bladder cauterization (16/60). Grades III and IV represent urological emergencies — clot retention can cause obstructive uropathy and renal failure that compound the already tenuous condition of a post-HSCT patient.
Risk Factors: Who Is Most Vulnerable?
Transplant-Related Risk Factors
We found that grade II–IV graft-versus-host disease (RR = 2.56), use of busulfan (RR = 2.69), and age at transplant (RR = 2.20) were significant risk factors for severe hemorrhagic cystitis following BMT.
The major risk factors for HC after HSCT are:
Conditioning regimen factors:
- Cyclophosphamide: the primary chemical risk factor — dose-dependent urothelial toxicity
- Busulfan: independently associated with HC when combined with cyclophosphamide — particularly the busulfan-cyclophosphamide (BuCy) conditioning regimen
- Total body irradiation (TBI): bladder irradiation contributes to urothelial fragility
- Intensity: myeloablative conditioning carries significantly higher HC risk than reduced-intensity conditioning
Transplant type factors:
- Allogeneic > autologous: allogeneic BMT recipients had more frequent HC than autologous patients (17% vs. 9%, P = 0.002) — reflecting both more intensive conditioning and the immune dysregulation of allogeneic graft-versus-host disease
- Mismatched/unrelated donors: greater HLA mismatch → more severe GVHD → more profound immunosuppression → greater BK virus reactivation risk
- Haploidentical transplantation with post-transplant cyclophosphamide: an emerging high-risk group as haploidentical transplants become more common
Viral factors:
- Pre-transplant BK viruria: pre-transplant BK viruria detected by quantitative PCR was positive in 96 patients — existing viral burden predicts post-transplant reactivation
- Adenoviruria: independent predictor of HC
Patient factors:
- Male sex: consistently associated with higher HC rates — possibly related to longer urethral exposure to urine
- Age: both young age (children) and older adults show higher HC rates in different series
Prevention: The First Line of Defense
Mesna: Standard of Care for Chemical HC
Mesna (2-mercaptoethane sulfonate sodium) is a sulfhydryl compound that reacts with acrolein in the urine — inactivating it before it reaches the urothelium. Combined with hyperhydration (aggressive IV fluid administration to dilute urinary acrolein), mesna has dramatically reduced the incidence of early chemical HC.
Current standard practice for cyclophosphamide-containing conditioning includes:
- Mesna at a dose equal to or exceeding cyclophosphamide dose
- Hyperhydration at 3–4 L/m²/day
- Forced diuresis with furosemide to minimize bladder dwell time of cyclophosphamide metabolites
- Frequent voiding protocols — patients are instructed to void every 2 hours during cyclophosphamide infusion
Continuous Bladder Irrigation
Continuous bladder irrigation prevents hemorrhagic cystitis after allogeneic hematopoietic cell transplantation. CBI — continuous saline infusion through a three-way urethral catheter — mechanically clears acrolein, blood, and clots from the bladder during the high-risk conditioning period and immediately post-transplant.
Prevention of Viral HC: A Harder Problem
Preventing BK virus-associated HC is fundamentally more difficult than preventing chemical HC — because it requires either preventing BK reactivation (currently not reliably achievable) or controlling it before it causes clinical disease:
- BK virus screening: serial urine PCR for BK virus allows early detection of reactivation before clinical HC develops
- Reducing immunosuppression: where clinically safe, tapering immunosuppression promotes immune reconstitution and BK control
- Prophylactic antiviral agents: ciprofloxacin and other fluoroquinolones have been studied for BK prophylaxis with inconsistent results; cidofovir is active against BK virus but nephrotoxic
Treatment: From Conservative to Surgical
The Management Ladder
When HC develops despite prevention, management follows an escalating stepwise approach:
Grade I–II (Mild to Moderate):
- Hyperhydration to maintain high urine output
- Analgesia — HC pain can be severe; bladder spasm requires antispasmodics
- For BK-associated HC: reduction of immunosuppression where feasible
Grade III (Clot Formation):
- Three-way catheter with continuous bladder irrigation — mandatory to prevent clot retention
- Manual bladder irrigation to break up and evacuate clots
- Cystoscopy if clots cannot be cleared with irrigation alone
Intravesical Therapies (Refractory Cases):
Sodium hyaluronate is a glycosaminoglycan present on the bladder mucosa, which serves as an important protective substance against uroepithelial damage. Preparations of this component have been shown to be effective in the treatment of interstitial cystitis. Intravesical sodium hyaluronate — instilled directly into the bladder — rebuilds the glycosaminoglycan layer protecting the damaged urothelium.
Other intravesical agents used in refractory HC include:
- Prostaglandin E₂: promotes mucosal healing and vasoconstriction
- Formalin: cauterizes bleeding points — reserved for life-threatening hemorrhage; significant toxicity risk
- Alum: astringent that causes protein precipitation and vessel constriction
Systemic Antiviral Therapy (BK Virus HC):
- Cidofovir: the most studied antiviral for BK virus — active but nephrotoxic; dose adjustment and probenecid co-administration required
- Leflunomide: immunomodulatory agent with anti-BK activity — used when cidofovir is contraindicated
Procedural and Surgical Interventions (Grade IV, Life-Threatening):
- Hyperbaric oxygen therapy: promotes urothelial healing through hyperoxia — effective in selected refractory cases
- Internal iliac artery embolization: reduces bladder blood supply to control catastrophic hemorrhage
- Cystectomy: last resort for life-threatening, uncontrollable bladder hemorrhage — rarely required but documented in extreme cases
Conclusion
Hemorrhagic cystitis after hematopoietic stem cell transplantation represents the clinical frontier where hematology and urology must function as genuine partners. Viral-induced HC is a common complication of allogeneic HSCT that remains a challenge for both hematologists and urologists. The hematologist manages the underlying transplant, viral reactivation, and immunosuppression; the urologist manages the bladder itself — clot evacuation, intravesical therapies, and surgical escalation when conservative measures fail.
Abbas Hajifathali’s early publication in the Urology Journal — a hematologist choosing a urological platform for his work — exemplifies the interdisciplinary collaboration that effective HC management demands. Prevention through mesna and hyperhydration has essentially solved the early chemical HC problem; late BK virus-associated HC remains the field’s most urgent challenge, requiring better prophylactic strategies, earlier diagnostic monitoring, and more effective antivirals.
Your next steps as a patient, caregiver, or clinician involved in HSCT:
- If you or a family member is preparing for HSCT, ask specifically about the conditioning regimen’s cyclophosphamide content and what HC prevention protocol — mesna dose, hyperhydration volume, bladder irrigation — will be used
- Know the early warning signs of HC: any pink, red, or tea-colored urine after HSCT should be reported immediately to the transplant team — early intervention prevents escalation to clot retention
- Understand that HC appearing weeks after transplant is almost certainly viral (BK or adenovirus), not chemical — the management is fundamentally different and requires prompt PCR testing to guide treatment
- Ask whether your transplant center performs serial BK virus urine PCR monitoring — early detection of BK reactivation before clinical HC develops allows preemptive reduction of immunosuppression
- If you are a urologist receiving a post-HSCT patient with severe HC, early cystoscopic clot evacuation and three-way catheter placement prevents the obstructive uropathy cascade — do not delay urological intervention in Grade III–IV HC while awaiting hematological management decisions
- Advocate for dedicated hematology-urology case conferences at your institution — multidisciplinary management planning for post-HSCT HC significantly improves outcomes compared to sequential single-specialty consultation